Open AccessMYC‐y mice: From tumour initiation to therapeutic targeting of endogenous MYC
Author(s) -
Morton Jennifer P.,
Sansom Owen J.
Publication year - 2013
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2013.02.015
Subject(s) - transgene , endogeny , genetically modified mouse , biology , proto oncogene proteins c myc , cancer research , genetically modified organism , computational biology , gene expression , gene , genetics , biochemistry
MYC is one of the best‐studied oncogenes in terms of mouse models of malignancy. MYC overexpression has been targeted to several tissues using transgenic constructs, and more recently as mouse models have evolved, conditional systems have been developed to allow the regulation of MYC expression or activity in vivo. The ability to target MYC expression to specific tissues and cell lineages, as well as the ability to regulate that expression, has made genetically engineered mouse models (GEMM) a valuable resource for studying the importance of MYC in the process of tumourigenesis. Here we review how these models have been used to address the role of MYC in tumour initiation and maintenance, how subtle changes in levels of MYC can influence tumourigenesis, and finally the ongoing efforts to target endogenous MYC genetically and with novel therapies.